Camidge R, et al. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: first report of a phase 3 trial (ALTA-1L). IASLC 2018, abstract PL02.03.
Lomustine-temozolomide vs. temozolomide bij glioblastoom met gemethyleerde MGMT-promotor
mrt 2019 | Neuro-oncologie